<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20171211037834N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-11-25</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison effect of submucosal injection and intravenous injection of ketamine on conscious sedation</public_title>
      <acronym></acronym>
      <scientific_title>Comparison effect of submucosal  injection and intravenous injection of ketamine on conscious sedation in patients who need wound repair in emergency department</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>184</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/42243</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: simple individualized randomization with random allocation software.</study_design>
      <phase>2-3</phase>
      <hc_freetext>sedation depth by ketamin in wound repair.</hc_freetext>
      <i_freetext>Intervention 1: Control group: 1.5 mg/kg  ketamin, rotexmedica Germany company production and with 28  gauge syringe intravenously. Intervention 2: Intervention group: 2mg/kg  ketamin, rotexmedica Germany company production and with 28 gauge syringe submocousally. Intervention 3: Intervention group: 3mg/kg  ketamin, rotexmedica Germany company production and with 28 gauge syringe submocousally. Intervention 4: Intervention group: 4mg/kg  ketamin, rotexmedica Germany company production and with 28 gauge syringe submocousally.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
all of data will be Shareable after unrecognizable patients.

When:
data will be available 1 year after release.

To whom:
data will be available just for research centers of universities.

Conditions:
analysis is permitted and special condition is not  considered.

Where to obtain:
availability request should be send via email with Introduction letter from research center.

How to obtain:
after request email received, an email for identity confirmation will be sent to research center.In case of confirmation, data will be send via email.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahdi Ahmadpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit 411, Mahtab Residential Complex, Ghadir Blvd, Sepahan Shahr</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8179949841</zip>
        <telephone>+98 31 3651 5338</telephone>
        <email>dr.ahmadpour.ma@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahdi Ahmadpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit 411, Mahtab Residential Complex, Ghadir Blvd, Sepahan Shahr</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8179949841</zip>
        <telephone>+98 31 3651 5338</telephone>
        <email>dr.ahmadpour.ma@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>children who are candidates for wound repair
patients without IV line before emergency department enterance
parents informed consent for study participation
2-8 years old</inclusion_criteria>
      <agemin>2 years</agemin>
      <agemax>8 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>ketamin sensitivity
physical or mental disability
immune systme diseases
another necessity for IV line fixation for patient
hypertension
recent seziures
thyroid diseases
glaucoma or acute globe injury
psychopathy
history of airway instability and tracheal stenosis
major procedures that cause posterior nasopharyngeal stimulation
active lung and upper airway infection
cardiovascular disease such as cardiac failure and angina pectoris
porphyria
major head trauma, CNS tumor, hydrocephalus</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: 1.5 mg/kg  ketamin, rotexmedica Germany company production and with 28  gauge syringe intravenously</i_keyword>
      <i_keyword>Intervention group: 2mg/kg  ketamin, rotexmedica Germany company production and with 28 gauge syringe submocousally</i_keyword>
      <i_keyword>Intervention group: 3mg/kg  ketamin, rotexmedica Germany company production and with 28 gauge syringe submocousally</i_keyword>
      <i_keyword>Intervention group: 4mg/kg  ketamin, rotexmedica Germany company production and with 28 gauge syringe submocousally</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sedation depth average. Timepoint: during procedure. Method of measurement: Ramsey score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Frequency distribution of doctors satisfaction. Timepoint: after procedure. Method of measurement: very bad(0), bad(1), usual(2), good(3), very good(4).</sec_outcome>
      <sec_outcome>Systolic blood pressure average. Timepoint: before, during, 5-10-15-30 min after injection. Method of measurement: Sphygmomanometer.</sec_outcome>
      <sec_outcome>Heart rate average. Timepoint: before, during, 5,10,15,30 min after injection. Method of measurement: cardiac monitor.</sec_outcome>
      <sec_outcome>O2 saturation percent average. Timepoint: before, during, 5-10-15-30 min after injection. Method of measurement: pulse oximetry.</sec_outcome>
      <sec_outcome>Respiratory rate average. Timepoint: before, during, 5-10-15-30 min after injection. Method of measurement: respiration in 1 minute.</sec_outcome>
      <sec_outcome>Admition duration average. Timepoint: during discharge. Method of measurement: admition duration in minute.</sec_outcome>
      <sec_outcome>Sedation duration average. Timepoint: during sedation. Method of measurement: since the patient dose not obey orders until the patient obeys orders again.</sec_outcome>
      <sec_outcome>Sedation onset average. Timepoint: drug administration. Method of measurement: from drug administration to disobedience onset.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-02-22</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>hezarjirib Avenue Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
